© 2022 MJH Life Sciences and NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.
The associate professor in the Department of Rehabilitation Medicine at NYU Langone provided insight on a recent study that utilized a novel digital tool to track the movement intensity of their stroke rehabilitation. [WATCH NOW: 4 minutes]
Each year, nearly 800,000 Americans suffer a stroke, according to estimates from the US Centers for Disease Control and Prevention. Rehabilitation interventions have improved over the years, but quantifying “dosing” and intensities for these approaches remains a challenge. In a recent analysis, a sensor-equipped computer program called Primseq was shown to accurately identify and count arm movements in post-stroke patients undergoing rehabilitation.
Led by Heidi Schambra, MD, a total of 41 patients post stroke who presented with moderate to mild impairment had sensors strapped to their arms and back to track movements in 3 dimensions. More than 51,616 upper body movements were recorded from 9 sensors, with the digital recordings of each arm movement then matched to functional categories, such as whether the movement involved reaching for an object or holding it still. Artificial intelligence software was then programmed to detect patterns within the data and tie these specific patterns to specific movements.1,2
To learn more about the study and the most notable take-home points clinicians should be aware of, NeurologyLive® sat down with Schambra. The associate professor in the Department of Neurology and Department of Rehabilitation Medicine at NYU Langone provided insight on the findings she observed, how the study was conducted, and advantages the Primseq tool may offer patients undergoing poststroke rehab.
Evusheld Increased Attenuated SARS-CoV-2 Antibodies From MS B-Cell Depleting Medications
Exploiting Anti-CD3 Antibodies, Relevant Biomarkers in Progressive MS: Tanuja Chitnis, MD
FDA Places Clinical Hold on Duchenne Muscular Dystrophy Drug SRP-5051 Amid Safety Concerns